DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 3, Pages e91440
Publisher
Public Library of Science (PLoS)
Online
2014-03-15
DOI
10.1371/journal.pone.0091440
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma
- (2013) K Gebauer et al. BRITISH JOURNAL OF CANCER
- A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
- (2013) Cora N. Sternberg et al. EUROPEAN JOURNAL OF CANCER
- A prognostic model for metastatic renal-cell carcinoma
- (2013) Matthew D Galsky LANCET ONCOLOGY
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma
- (2012) Christoph Seidel et al. EUROPEAN JOURNAL OF CANCER
- Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer
- (2012) Sakari Vanharanta et al. NATURE MEDICINE
- Epigenetic regulation in RCC: opportunities for therapeutic intervention?
- (2012) James Larkin et al. Nature Reviews Urology
- RECIST rules
- (2012) Aslam Sohaib CANCER IMAGING
- Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
- (2011) Maxine Sun et al. EUROPEAN UROLOGY
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
- (2011) Jesus Garcia-Donas et al. LANCET ONCOLOGY
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
- (2011) Ignacio Varela et al. NATURE
- TNM seventh edition: What's new, what's changed
- (2010) Leslie H Sobin et al. CANCER
- Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
- (2010) Gillian L. Dalgliesh et al. NATURE
- Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma
- (2010) M A T Hildebrandt et al. ONCOGENE
- Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma
- (2010) M R Morris et al. ONCOGENE
- Prognostic Significance of Gremlin1 (GREM1) Promoter CpG Island Hypermethylation in Clear Cell Renal Cell Carcinoma
- (2009) Iris J.H. van Vlodrop et al. AMERICAN JOURNAL OF PATHOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- The Impact of Immune Gene Polymorphisms in Kidney and Liver Transplantation
- (2008) Peter Nickerson CLINICS IN LABORATORY MEDICINE
- von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma
- (2008) Toni K. Choueiri et al. JOURNAL OF UROLOGY
- Progression-free survival as endpoint in metastatic RCC?
- (2008) Jennifer J Knox LANCET
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started